Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00148941 · ClinicalTrials.gov registry record · Phase 3

Immune Response and Safety Comparison of 3 Lots of GSK Biologicals' DTaP-IPV Candidate Vaccine to DTaP + IPV Vaccines

A Phase 3 study of Diphtheria and Tetanus, sponsored by GlaxoSmithKline.

Completed
Registry status
Phase 3
Development phase
4,209
Enrollment target
20
Study locations

NCT00148941: Completed Phase 3 study of Diphtheria and Tetanus, sponsored by GlaxoSmithKline.

NCT00148941 is a Phase 3 study of Diphtheria and Tetanus that has completed, run by GlaxoSmithKline. The registered enrollment target is 4,209 participants, above the 1,586-participant average among 15 other Diphtheria trials with a reported enrollment target (165% higher). The trial reports 20 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00148941, a Phase 3 study of Diphtheria and Tetanus, has completed, sponsored by GlaxoSmithKline.

COMPLETED
Registry status
Phase 3
Development phase
4,209 participants
Enrollment target
20
Study locations

Study Summary

The aims of this trial are to demonstrate the consistency of three manufacturing lots of GSK Biologicals' DTaP-IPV candidate vaccine in terms of immunogenicity and to evaluate the non-inferiority of GSK Biologicals' DTaP-IPV vaccine with respect to immunogenicity and safety compared to the control vaccines (separate injections of GSK Biologicals' DTaP vaccine \[Infanrix\] and Aventis Pasteur's IPV vaccine \[IPOL\]) when administered as a 5th dose of DTaP and a 4th dose of inactivated poliovirus vaccine in subjects 4 to 6 years of age. Vaccines will be co-administered with the second dose of M-M-RII, which is recommended at this age. Concomitant administration of a US-licensed influenza vaccine will be allowed according to seasonal availability of vaccine and at the discretion of the investigator.

Primary Outcome

GMCs were measured by Enzyme-Linked Immunosorbent assay (ELISA), expressed in international units per milliliter (IU/mL).

Conditions Studied

Diphtheria Tetanus Acellular Pertussis

Interventions

  • BIOLOGICAL SB213503 lot 1
  • BIOLOGICAL SB213503 lot 2
  • BIOLOGICAL SB213503 lot 3
  • BIOLOGICAL Infanrix
  • BIOLOGICAL IPOL

Study Locations (20)

California

  • GSK Investigational Site - Antioch
  • GSK Investigational Site - Daly City
  • GSK Investigational Site - Fairfield
  • GSK Investigational Site - Fremont
  • GSK Investigational Site - Fresno
  • GSK Investigational Site - Hayward
  • GSK Investigational Site - Oakland
  • GSK Investigational Site - Pleasanton
  • GSK Investigational Site - Redwood City
  • GSK Investigational Site - Richmond
  • GSK Investigational Site - Roseville
  • GSK Investigational Site - Sacramento
  • GSK Investigational Site - Sacramento
  • GSK Investigational Site - San Francisco
  • GSK Investigational Site - San Jose
  • GSK Investigational Site - San Ramon
  • GSK Investigational Site - Santa Clara
  • GSK Investigational Site - Santa Rosa
  • GSK Investigational Site - Vacaville

Arkansas

  • GSK Investigational Site - Little Rock

Trial Details

FieldValue
Enrollment Target 4,209 participants
Start Date 2005-01-06
Est. Completion 2006-12-04
Phase Phase 3
GlaxoSmithKline

1,345 total trials

What the finished NCT00148941 record still lists

NCT00148941 is an interventional study that assigns participants to a tested intervention. Its 4,209 participants enrollment target places it among the larger protocols in the corpus, above the 1,586-participant average among 15 other Diphtheria trials with a reported enrollment target (165% higher).

The record links to 3 conditions, with Diphtheria appearing as the primary indexed condition, and to 5 interventions - of which SB213503 lot 1 is the first listed.

NCT00148941 names 20 study sites across 2 states, led by California, Arkansas.

Frequently Asked Questions

What is clinical trial NCT00148941 about?

NCT00148941 is a clinical study titled "Immune Response and Safety Comparison of 3 Lots of GSK Biologicals' DTaP-IPV Candidate Vaccine to DTaP + IPV Vaccines". The aims of this trial are to demonstrate the consistency of three manufacturing lots of GSK Biologicals' DTaP-IPV candidate vaccine in terms of immunogenicity and to evaluate the non-inferiority of GSK Biologicals' DTaP-IPV vaccine with respect to immunogenicity and safety compared to the control v...

What is the current status of trial NCT00148941?

This trial is currently completed. It is a Phase 3 study. The enrollment target is 4,209 participants. The study started on 2005-01-06. Estimated completion is 2006-12-04.

What conditions does trial NCT00148941 study?

This clinical trial studies the following conditions: Diphtheria, Tetanus, Acellular Pertussis.

What interventions are being tested in trial NCT00148941?

The interventions under investigation include: SB213503 lot 1 (BIOLOGICAL), SB213503 lot 2 (BIOLOGICAL), SB213503 lot 3 (BIOLOGICAL), Infanrix (BIOLOGICAL), IPOL (BIOLOGICAL).

Who is sponsoring clinical trial NCT00148941?

This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00148941 being conducted?

This trial has 20 study locations across Arkansas, California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Diphtheria

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT00148941's enrollment target sits among peer trials

4,209 2nd of 15 the highest of 15 other Diphtheria trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Diphtheria trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02693535 · 4,200 participants · Phase 2

    TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer

  • NCT05969028 · 4,200 participants · NA

    First Responder Airway & Compression Rate Trial

  • NCT06935370 · 4,200 participants · Phase 3

    A Study to Test Whether Vicadrostat (BI 690517) in Combination With Empagliflozin Helps People With Heart Failure and a Weak Pumping Function of the Left Side of the Heart

  • NCT07209098 · 4,200 participants

    Propensity-Matched Study of Cardiac Contractility Modulation Therapy in Heart Failure

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Related registry views

Source: ClinicalTrials.gov NCT00148941, the US trial registry maintained by the National Library of Medicine. NCT00148941 (large enrollment · wide site footprint · completed) retrieved and formatted by PlainTrial, see methodology.